Previously, Cifola et al. reported that the frequency of KRAS/NRAS mutations was low in plasma cell leukemia, which is the aggressive and high-risk form of plasma cell dyscrasia [31]. This evidence concerns the gene KRAS and plasma cell neoplasm.